Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed…(PANORAMA-5) | Phase 2 | withdrawn | Apr 29, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00255684 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and… | N/A | terminated | Nov 21, 2005 | University of Rochester | low accrual | Enrollment / accrual |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to… | Phase 2 | terminated | Dec 25, 2013 | Attaya Suvannasankha | Slow accrual | Enrollment / accrual |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | Phase 2 | terminated | Oct 3, 2012 | Greg Monohan | Research cancelled following interim analysis | Efficacy / futility |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple… | Phase 1 | terminated | Jun 3, 2009 | Cougar Biotechnology, Inc. | Terminated early due to lack of clinical response. | Other (stated, no rule matched) |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in… | Phase 1 / Phase 2 | withdrawn | Nov 16, 2015 | Bayer | Study restarted under new study number 18987 | Other (stated, no rule matched) |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | N/A | terminated | Aug 26, 2011 | Merck KGaA, Darmstadt, Germany | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | Phase 2 | terminated | Oct 12, 2015 | Henrik Gregersen | Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide… | Other (stated, no rule matched) |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 | terminated | Nov 15, 2013 | M.D. Anderson Cancer Center | Terminated Phase I due to slow accrual without progression to Phase II. | Enrollment / accrual |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in… | Phase 2 / Phase 3 | terminated | Sep 25, 2009 | Shanghai Jiao Tong University School of Medicine | Very slow recruitment | Enrollment / accrual |
| NCT02230917 | A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple… | Phase 2 | withdrawn | Sep 3, 2014 | Rebecca Silbermann | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | Phase 2 | terminated | Mar 31, 2010 | Jagannath, Sundar, M.D. | The research is permanently closed to enrollment. | Enrollment / accrual |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | Phase 3 | terminated | Apr 15, 2016 | Hoffmann-La Roche | Slow recruitment | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | Early Phase 1 | withdrawn | May 18, 2015 | Washington University School of Medicine | not stated | Not stated |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase 2 | terminated | Sep 24, 2009 | University of Utah | Lab Staff that was required left the institution, therefore accrual closed prematurely | Enrollment / accrual |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2012 | National Cancer Institute (NCI) | study closed prematurely because investigator left National Institutes of Health | Investigator |
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic… | Phase 1 | terminated | Aug 16, 2010 | University of Rochester | low enrollment | Enrollment / accrual |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | Phase 1 | terminated | Mar 8, 2013 | M.D. Anderson Cancer Center | Sponsor requested termination | Other (stated, no rule matched) |
| NCT00892346 | Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line… | Phase 3 | suspended | May 4, 2009 | Shanghai Jiao Tong University School of Medicine | No avaliability of melphlan in mainland China | Other (stated, no rule matched) |
| NCT01501370 | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in…(ZLd_Ld) | Phase 2 | withdrawn | Dec 29, 2011 | Tiziana Marangon | not stated | Not stated |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT01016028 | Chemotherapy-Induced Peripheral Neuropathy Survey | — | withdrawn | Nov 18, 2009 | M.D. Anderson Cancer Center | Study assessment tool development delayed. | Other (stated, no rule matched) |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of… | Phase 1 / Phase 2 | terminated | Dec 2, 2009 | Cephalon | not stated | Not stated |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the… | Phase 2 | withdrawn | May 16, 2014 | University of Arkansas | PI left institution | Investigator |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity… | Phase 2 | terminated | Feb 14, 2008 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | Phase 2 | terminated | Jan 25, 2012 | M.D. Anderson Cancer Center | Objectives not met. | Other (stated, no rule matched) |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2011 | University of Pittsburgh | Clinical trial being transferred to Columbia University with the Investigator. | Investigator |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | Phase 1 | withdrawn | Dec 20, 2007 | University of Arkansas | no accrual | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With… | Phase 1 | terminated | Jun 28, 2013 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed,… | Phase 2 | terminated | Feb 5, 2007 | Valerio Therapeutics | Terminated due to dose limiting toxicity | Safety / toxicity |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With… | Phase 3 | terminated | Aug 29, 2007 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Enrollment terminated in 2005 to focus on Phase 3 study enrollment. | Enrollment / accrual |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple… | Phase 2 | withdrawn | Mar 10, 2014 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | Phase 2 | withdrawn | Jul 19, 2007 | Meir Medical Center | We found out that there is another study on the same issue | Other (stated, no rule matched) |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients… | Phase 4 | withdrawn | Oct 20, 2005 | Novartis | not stated | Not stated |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed… | Phase 2 | withdrawn | Jun 30, 2008 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | not stated | Not stated |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Feb 4, 2010 | University of Arkansas | Slow accrual; PI left primary institution | Investigator |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | N/A | terminated | Sep 8, 2008 | Assistance Publique - Hôpitaux de Paris | the data collected are enough to obtain a qualitative analysis. | Other (stated, no rule matched) |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients… | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory… | Phase 3 | terminated | Mar 16, 2004 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous… | Phase 2 | withdrawn | Jan 25, 2010 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 8, 2016source: clinicaltrials